GLP-3 RT is a triple-agonist peptide designed to simultaneously activate GLP-1, GIP, and glucagon (GCGR) receptors.
This tri-pathway mechanism provides unmatched fat-loss efficiency, glucose stability, and metabolic flexibility, addressing multiple energy-regulation systems at once. By stimulating both incretin and glucagon pathways, Retatrutide enhances energy expenditure, lipid utilization, and overall metabolic rejuvenation.

RESEARCH

GLP-3 RT is a synthetic, multi-site peptide analog provided in lyophilized powder form for exclusive use in qualified laboratory environments. This product has not been evaluated by the FDA and is intended solely for in vitro research to explore peptide-receptor interactions and structural modifications under controlled, non-clinical research settings. Use is restricted to trained laboratory personnel in facilities with appropriate safety protocols and institutional oversight.

Chemical Information:

• Molecular Formula: C221H342N46O68
• Molecular Weight: 4845.44 g/mol
• Sequence: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3

Research Applications:

• Receptor-ligand modeling involving peptide analogs
• Evaluation of synthetic conjugation strategies in non-human systems
• Peptide degradation analysis and structural integrity assays
• Receptor pathway simulation and screening assay development

Storage and Handling:

• Store lyophilized powder at -20°C
• Reconstituted compound should be kept at 2–8°C and used promptly
• Always use sterile technique during handling and preparation.
• Users must follow institutional safety protocols, including appropriate personal protective equipment (PPE) and biosafety measures as required by facility guidelines and applicable regulations. Documentation of proper handling procedures must be maintained.

Product Specifications:

• Purity: ≥99% (HPLC Verified)
• Appearance: Lyophilized white to off-white powder
• Solubility: Soluble in bacteriostatic water

Compliance Notice:

GLP-3 RT is FOR RESEARCH USE ONLY. Not for human or veterinary use. This product has not been evaluated by the FDA. Not intended for therapeutic, diagnostic, or clinical applications. Any misuse of this material may be subject to regulatory enforcement. By purchasing this product, buyer represents and warrants that it will be used only for in vitro research purposes.

Key Benefits:

• Maximizes weight-loss potential through triple incretin activation
• Improves glycemic control while maintaining lean-mass retention
• Boosts basal metabolic rate and increases fat oxidation
• Improves cardiovascular and lipid profiles (↓ triglycerides, ↑ HDL)
• Enhances mitochondrial activity and glucose uptake in muscle tissue
• Promotes appetite control and satiety via central metabolic signaling

Mechanism of Action (Simplified):

• GLP-1 Receptor Activation → enhances insulin secretion, slows gastric emptying, suppresses appetite.
• GIP Receptor Activation → improves insulin sensitivity and lipid metabolism.
• Glucagon Receptor Activation (GCGR) → stimulates fat oxidation and energy expenditure.
• Tri-pathway synergy → balanced improvement in glucose regulation, lipid turnover, and adipose reduction.

Applications / Possible Uses:

• Advanced obesity and metabolic-syndrome research
• Comparative studies of single vs. multi-agonist incretin therapy
• Non-alcoholic fatty-liver (NASH) and lipid-metabolism protocols
• Combination therapy with Cagrilintide or 5-Amino-1MQ for maximal metabolic effect

Form / Notes:

• Lyophilized peptide for reconstitution
• Standard metabolic-research dosing